시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 로사이돌프만병 시장 보고서(2025년)
Rosai-Dorfman Disease Global Market Report 2025
상품코드 : 1769736
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

로사이돌프만병 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 의료 플랫폼의 이용 증가, 질환 관련 유전자 마커의 지속적인 동정 등으로부터 가져올 것으로 예측됩니다. 향후의 동향으로서 주목받는 것은 진단 프로세스에 있어서의 인공지능의 이용, 디지털 헬스 기술의 확대, 학술 기관과 업계 이해 관계자의 제휴 노력, 질환 특이적 치료 프로토콜의 작성, 유전체 해석 전략의 진전 등입니다.

표적 요법에 대한 수요가 증가함에 따라 로사이돌프만병 시장의 성장을 이끌 것으로 예측됩니다. 정확하게 목표를 쏘고 건강한 조직에 대한 손상을 최소화함으로써 기존 치료법보다 부작용이 적고 치료 성적 향상으로 이어지므로 수요가 확대되고 있습니다. K/ERK와 같은 중요한 경로를 차단하여 기능을 낮추고 질병을 효과적으로 관리합니다. 2023년 7월, 미국 유전자 및 세포 치료 학회(ASGCT)는 2023년 3분기에 임상 2상 단계에 있는 표적 유전자 치료제가 247개에 달하여, 2분기 대비 5% 증가했음을 보고했습니다. 그 결과 표적 치료에 대한 수요 증가가 로사이돌프만병 시장의 확대에 기여하고 있습니다.

또한 면역 관련 합병증 증가는 로사이돌프만병 시장의 성장을 지원할 것으로 예측됩니다. 이 증가는 과도한 면역 반응을 일으켜 염증과 건강한 조직에 손상을 줄 수있는 면역 요법의 사용 증가로 인한 것입니다. 면역 체계 조절 장애와 관련이 있으며, 자가면역 질환, 감염 또는 면역 요법 부작용으로 인한 면역 관련 합병증의 증가가 이 질환의 발병 또는 악화에 기여하는 것으로 여겨집니다. 이 동향은 진단, 연구 주목, 치료 개발의 확대를 촉진하고 있습니다. Versorgungsatlas.de의 보고서에 따르면 2022년 독일의 건강보험 가입자 7,324만 1,305명 중 630만 4,340명이 적어도 한 가지 이상의 자가면역질환으로 진단되었으며, 유병률은 8.61%였습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Rosai-Dorfman disease is an uncommon, non-cancerous condition marked by an excessive accumulation of a particular immune cell known as histiocytes, primarily within lymphatic tissues. It typically manifests as large, painless swelling of lymph nodes, especially in the cervical region, though other organs and tissues can also be involved. Diagnosis is usually confirmed through biopsy and pathological analysis, and treatment approaches range from watchful waiting to surgical intervention or the use of immunosuppressive medications, depending on the disease's severity and the organs affected.

The primary forms of Rosai-Dorfman disease include classic (nodal) Rosai-Dorfman disease and extranodal Rosai-Dorfman disease. Classic (nodal) Rosai-Dorfman disease mainly affects lymph nodes in the neck, presenting with painless enlargement, and is the most frequently observed type. Treatment encompasses various procedural approaches, such as diagnostic and therapeutic measures, and is delivered via multiple administration routes, including oral, parenteral, sublingual, and nasal. The disease affects both pediatric and adult populations, and the main end-users include hospitals, diagnostic laboratories, oncology centers, and other healthcare providers.

The Rosai-Dorfman disease market research report is one of a series of new reports from The Business Research Company that provides rosai-dorfman disease market statistics, including the rosai-dorfman disease industry global market size, regional shares, competitors with the rosai-dorfman disease market share, detailed rosai-dorfman disease market segments, market trends, opportunities, and any further data you may need to thrive in the rosai-dorfman disease industry. This rosai-dorfman disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rosai-dorfman disease market size has grown strongly in recent years. It will grow from $0.50 billion in 2024 to $0.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. Growth during the historical period was driven by heightened diagnostic recognition, increased incidences of clinical misidentification, greater dependency on invasive biopsy methods, expansion of the population with undiagnosed cases, and a persistent lack of targeted therapeutic options.

The rosai-dorfman disease market size is expected to see strong growth in the next few years. It will grow to $0.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. This future expansion is anticipated to result from broader adoption of molecular diagnostic techniques, elevated awareness surrounding rare diseases, intensified clinical research activity, improved healthcare service availability, increased use of telemedicine platforms, and the ongoing identification of disease-related genetic markers. Notable upcoming trends include the use of artificial intelligence in diagnostic processes, expansion of digital health technologies, collaborative efforts between academic institutions and industry stakeholders, the creation of condition-specific treatment protocols, and the advancement of genomic analysis strategies.

The increasing demand for targeted therapies is expected to drive the growth of the Rosai-Dorfman disease market. Targeted therapies are precision drugs designed to attack specific genetic mutations or cellular mechanisms that promote tumor development, while sparing healthy cells. This demand is growing due to their ability to precisely target disease-causing cells, minimizing damage to healthy tissues, and leading to improved treatment outcomes with fewer side effects than traditional therapies. In the context of Rosai-Dorfman disease, targeted therapies work by blocking critical pathways such as MAPK/ERK that lead to abnormal histiocyte growth, effectively managing the disease with fewer adverse effects. These treatments focus on disease-specific mechanisms, avoiding harm to unaffected tissues. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) reported that there were 247 targeted gene therapies in Phase II in the third quarter of 2023, reflecting a 5% increase compared to the second quarter. As a result, the growing demand for targeted therapies is contributing to the expansion of the Rosai-Dorfman disease market.

The increase in immune-related complications is also anticipated to support the growth of the Rosai-Dorfman disease market. Immune-related complications occur when an overactive or dysfunctional immune system causes harm, often in connection with infections, autoimmune disorders, or immunotherapies. This rise is largely driven by the increased use of immunotherapy, which can lead to an overactive immune response, resulting in inflammation or damage to healthy tissues. Rosai-Dorfman disease is associated with immune system dysregulation, and the growing number of immune-related complications from autoimmune diseases, infections, or immunotherapy side effects is believed to contribute to the onset or exacerbation of the condition. This trend has prompted greater diagnosis, research attention, and therapeutic development. For instance, in November 2024, Versorgungsatlas.de reported that out of 73,241,305 insured individuals in Germany, 6,304,340 were diagnosed with at least one autoimmune disease in 2022, indicating a raw prevalence rate of 8.61%. Therefore, the rising rate of immune-related complications is playing a significant role in advancing the Rosai-Dorfman disease market.

Leading companies in the Rosai-Dorfman disease market are increasingly focused on the development of advanced targeted drugs that inhibit specific molecular pathways responsible for abnormal histiocyte proliferation, aiming to reduce disease severity. Targeted drugs act on particular proteins or genes driving the disease, thereby enhancing treatment precision and minimizing harm to healthy tissues. In October 2022, Memorial Sloan Kettering, a U.S.-based cancer treatment and research center, introduced cobimetinib (Cotellic), a drug approved by the U.S. Food and Drug Administration (FDA). This marked the first approved treatment for adults with Rosai-Dorfman disease and other types of histiocytosis. The therapy represents a major advancement, offering a less toxic, more precise alternative to traditional chemotherapy. It improves patients' quality of life and offers new hope for long-term disease management in individuals affected by these rare blood disorders.

Major players in the rosai-dorfman disease market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche AG, Merck And Co. Inc., Bristol Myers Squibb Company, Novartis AG, Canon Inc., Siemens Healthineers, GE HealthCare, Viatris Inc., Teva Pharmaceutical Industries Ltd., Memorial Sloan Kettering Cancer Center, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Mayo Foundation for Medical Education and Research, Zydus Pharmaceuticals Inc., SternMed GmbH, LGM Pharma, Niksan Pharmaceutical, Herbert Irving Cancer Center.

North America was the largest region in the rosai-dorfman disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rosai-dorfman disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rosai-dorfman disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rosai-dorfman disease market consists of revenues earned by entities by providing services such as diagnostic services, clinical services, therapeutic services, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The rosai-dorfman disease market consists of sales of immunohistochemistry (IHC) kits and reagents, molecular diagnostic kits, targeted therapy drugs, magnetic resonance imaging, and computed tomography scans. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rosai-Dorfman Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rosai-dorfman disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for rosai-dorfman disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rosai-dorfman disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Rosai-Dorfman Disease Market Characteristics

3. Rosai-Dorfman Disease Market Trends And Strategies

4. Rosai-Dorfman Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Rosai-Dorfman Disease Growth Analysis And Strategic Analysis Framework

6. Rosai-Dorfman Disease Market Segmentation

7. Rosai-Dorfman Disease Market Regional And Country Analysis

8. Asia-Pacific Rosai-Dorfman Disease Market

9. China Rosai-Dorfman Disease Market

10. India Rosai-Dorfman Disease Market

11. Japan Rosai-Dorfman Disease Market

12. Australia Rosai-Dorfman Disease Market

13. Indonesia Rosai-Dorfman Disease Market

14. South Korea Rosai-Dorfman Disease Market

15. Western Europe Rosai-Dorfman Disease Market

16. UK Rosai-Dorfman Disease Market

17. Germany Rosai-Dorfman Disease Market

18. France Rosai-Dorfman Disease Market

19. Italy Rosai-Dorfman Disease Market

20. Spain Rosai-Dorfman Disease Market

21. Eastern Europe Rosai-Dorfman Disease Market

22. Russia Rosai-Dorfman Disease Market

23. North America Rosai-Dorfman Disease Market

24. USA Rosai-Dorfman Disease Market

25. Canada Rosai-Dorfman Disease Market

26. South America Rosai-Dorfman Disease Market

27. Brazil Rosai-Dorfman Disease Market

28. Middle East Rosai-Dorfman Disease Market

29. Africa Rosai-Dorfman Disease Market

30. Rosai-Dorfman Disease Market Competitive Landscape And Company Profiles

31. Rosai-Dorfman Disease Market Other Major And Innovative Companies

32. Global Rosai-Dorfman Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rosai-Dorfman Disease Market

34. Recent Developments In The Rosai-Dorfman Disease Market

35. Rosai-Dorfman Disease Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기